Zydus Medtech, Braile Biomedica, Brazil, partner to commercialise TAVI technology

Zydus MedTech, a wholly owned subsidiary of Zydus Lifesciences, has entered into a strategic partnership with Braile Biomédica Indústria, Comércio e Representações (Braile Biomedica) – a cardiovascular device manufacturer based in Brazil – to exclusively commercialise its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets.

The global TAVI market, currently valued at over $ 6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures.

Zydus MedTech will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets. Braile Biomedica – with a proven track record in cardiovascular innovation, particularly in Latin America – will manufacture and supply the product for these markets.

In addition to spearheading commercialisation, Zydus MedTech will also retain rights to manufacture select components of the TAVI system. 

The system was developed based on the doctoral thesis of Dr Domingo Braile, a pioneer of cardiac surgery in Brazil. Braile’s valve features a bovine pericardium sheet, used as a single piece rather than three separate leaflets, ensuring exceptional biocompatibility, durability, and performance.

The device must be collapsible, navigable through complex vascular anatomy, and fully functional upon deployment — all while maintaining structural integrity. This engineering precision and real-time deployment capability exemplify the fusion of innovation and performance, making it a next-generation, high-value product in cardiac care.

Over the next three years, the partnership aims to launch a series of innovations, supported by a clinical research programme beginning next year in the regions covered under the agreement.